Unravelling the therapeutic potential of forkhead box proteins in breast cancer: An update (Review)
- Authors:
- Sadaf Anwar
- Mubashir Zafar
- Malik Asif Hussain
- Naveed Iqbal
- Abrar Ali
- Sadaf
- Simran Kaur
- Mohammad Zeeshan Najm
- Mohd Adnan Kausar
-
Affiliations: Department of Biochemistry, College of Medicine, University of Ha'il, Ha'il 2440, Saudi Arabia, Department of Family and Community Medicine, College of Medicine, University of Ha'il, Ha'il 2440, Saudi Arabia, Department of Pathology, College of Medicine, University of Ha'il, Ha'il 2440, Saudi Arabia, Department of Obstetrics and Gynecology, College of Medicine, University of Ha'il 2440, Saudi Arabia, Department of Ophthalmology, College of Medicine, University of Ha'il 2440, Saudi Arabia, Department of Biotechnology, Jamia Millia Islamia, New Delhi 110025, India, School of Biosciences, Apeejay Stya University, Sohna, Gurugram, Haryana 122103, India - Published online on: June 4, 2024 https://doi.org/10.3892/or.2024.8751
- Article Number: 92
-
Copyright: © Anwar et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Weiderpass E and Stewart BW: World cancer report: Cancer research for cancer prevention. International Agency for Research on Cancer; Lyon: 2020 | |
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5:77–106. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Laissue P: The forkhead-box family of transcription factors: Key molecular players in colorectal cancer pathogenesis. Mol Cancer. 18:52019. View Article : Google Scholar : PubMed/NCBI | |
|
Bach DH, Long NP, Luu TT, Anh NH, Kwon SW and Lee SK: The dominant role of forkhead box proteins in cancer. Int J Mol Sci. 19:32792018. View Article : Google Scholar : PubMed/NCBI | |
|
Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Weigel D, Jürgens G, Küttner F, Seifert E and Jäckle H: The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell. 57:645–658. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Vaidya HJ, Briones Leon A and Blackburn CC: FOXN1 in thymus organogenesis and development. Eur J Immunol. 46:1826–1837. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lam EW and Gomes AR: Forkhead box transcription factors in cancer initiation, progression and chemotherapeutic drug response. Front Oncol. 4:3052014. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Zhang K, Chen J, Chen L, Wang R and Chu X: MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers. Oncotarget. 8:12433–12450. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Seachrist DD, Anstine LJ and Keri RA: FOXA1: A pioneer of nuclear receptor action in breast cancer. Cancers (Basel). 13:52052021. View Article : Google Scholar : PubMed/NCBI | |
|
Czerny CC, Borschel A, Cai M, Otto M and Hoyer-Fender S: FOXA1 is a transcriptional activator of Odf2/Cenexin and regulates primary ciliation. Sci Rep. 12:214682022. View Article : Google Scholar : PubMed/NCBI | |
|
Cirillo LA and Zaret KS: Specific interactions of the wing domains of FOXA1 transcription factor with DNA. J Mol Biol. 366:720–724. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bernardo GM and Keri RA: FOXA1: A transcription factor with parallel functions in development and cancer. Biosci Rep. 32:113–130. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, Cheng H, Bai Z and Li J: Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 8:3131–3141. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhao Y, Skerry B, Wang X, Colin-Cassin C, Radisky DC, Kaestner KH and Li Z: Foxa1 is essential for mammary duct formation. Genesis. 54:277–285. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brisken C and O'Malley B: Hormone action in the mammary gland. Cold Spring Harb Perspect Biol. 2:a0031782010. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG and Carroll JS: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 30:3019–3027. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang YA, Zhao JC, Fong KW, Kim J, Li S, Song C, Song B, Zheng B, He C and Yu J: FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function. Nucleic Acids Res. 44:8153–8164. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, et al: FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development. 137:2045–2054. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Takaku M, Grimm SA, De Kumar B, Bennett BD and Wade PA: Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3. Nucleic Acids Res. 48:4756–4768. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh S, Gu F, Wang CM, Lin CL, Liu J, Wang H, Ravdin P, Hu Y, Huang TH and Li R: Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1. Breast Cancer Res Treat. 147:653–659. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Slebe F, Rojo F, Vinaixa M, García-Rocha M, Testoni G, Guiu M, Planet E, Samino S, Arenas EJ, Beltran A, et al: FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth. Nat Commun. 7:111992016. View Article : Google Scholar : PubMed/NCBI | |
|
Anzai E, Hirata K, Shibazaki M, Yamada C, Morii M, Honda T and Yamaguchi N and Yamaguchi N: FOXA1 induces E-cadherin expression at the protein level via suppression of slug in epithelial breast cancer cells. Biol Pharm Bull. 40:1483–1489. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ambrosone CB and Higgins MJ: Relationships between breast feeding and breast cancer subtypes: Lessons learned from studies in humans and in mice. Cancer Res. 80:4871–4877. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xia K, Huang W, Zhao X, Huang X, Chen Y, Yu L and Tan Y: Increased FOXA1 levels induce apoptosis and inhibit proliferation in FOXA1-low expressing basal breast cancer cells. Am J Cancer Res. 12:2641–2658. 2022.PubMed/NCBI | |
|
Cantor JR and Sabatini DM: Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2:881–898. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhou Y and Graves DT: FOXO transcription factors: Their clinical significance and regulation. Biomed Res Int. 2014:9253502014.PubMed/NCBI | |
|
Jiramongkol Y and Lam EW: FOXO transcription factor family in cancer and metastasis. Cancer Metastasis Rev. 39:681–709. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dumont SN, Lazar AJ, Bridge JA, Benjamin RS and Trent JC: PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. J Cancer Res Clin Oncol. 138:213–220. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Parry P, Wei Y and Evans G: Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer. 11:79–84. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Guttilla IK and White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bullock M: FOXO factors and breast cancer: Outfoxing endocrine resistance. Endocr Relat Cancer. 23:R113–R130. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J and Zheng W: FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Di Blasio L, Gagliardi PA, Puliafito A and Primo L: Serine/threonine kinase 3-phosphoinositide-dependent protein Kinase-1 (PDK1) as a key regulator of cell migration and cancer dissemination. Cancers (Basel). 9:252017. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tzivion G, Dobson M and Ramakrishnan G: FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 1813:1938–1945. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim S, Kim Y, Lee J and Chung J: Regulation of FOXO1 by TAK1-Nemo-like kinase pathway. J Biol Chem. 285:8122–8129. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Liu K and Dong Z: The role of p21-activated kinases in cancer and beyond: Where are we heading? Front Cell Dev Biol. 9:6413812021. View Article : Google Scholar : PubMed/NCBI | |
|
Khan MA, Massey S, Ahmad I, Sada f, Akhter N, Habib M, Mustafa S, Deo SVS and Husain SA: FOXO1 gene downregulation and promoter methylation exhibits significant correlation with clinical parameters in Indian breast cancer patients. Front Genet. 13:8429432022. View Article : Google Scholar : PubMed/NCBI | |
|
Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD and Lam EW: SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 9:844–855. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gong C, Yao S, Gomes AR, Man EP, Lee HJ, Gong G, Chang S, Kim SB, Fujino K, Kim SW, et al: BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. Oncogenesis. 5:e2142016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y, Jiang G, Lu M, Zhang Z, Yin J, et al: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 27:966–983. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sanders DA, Gormally MV, Marsico G, Beraldi D, Tannahill D and Balasubramanian S: FOXM1 binds directly to non-consensus sequences in the human genome. Genome Biol. 16:1302015. View Article : Google Scholar : PubMed/NCBI | |
|
Korver W, Roose J, Heinen K, Weghuis DO, de Bruijn D, van Kessel AG and Clevers H: The human TRIDENT/HFH-11/FKHL16 gene: Structure, localization, and promoter characterization. Genomics. 46:435–442. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kalathil D, John S and Nair AS: FOXM1 and cancer: Faulty cellular signaling derails homeostasis. Front Oncol. 10:6268362021. View Article : Google Scholar : PubMed/NCBI | |
|
Ye H, Kelly TF, Samadani U, Lim L, Rubio S, Overdier DG, Roebuck KA and Costa RH: Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol Cell Biol. 17:1626–1641. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Halasi M and Gartel AL: FOX(M1) news-it is cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, Feng XH, Sawaya R, Medema RH, Hung MC and Huang S: Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Invest. 124:564–579. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Speirs V and Walker RA: New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol. 211:499–506. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Iqbal N and Iqbal N: Human epidermal growth factor Receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI | |
|
Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, et al: FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol. 35:57–68. 2009.PubMed/NCBI | |
|
Chen X, Wei H, Li J, Liang X, Dai S, Jiang L, Guo M, Qu L, Chen Z, Chen L and Chen Y: Structural basis for DNA recognition by FOXC2. Nucleic Acids Res. 47:3752–3764. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pierrou S, Enerbäck S and Carlsson P: Selection of high-affinity binding sites for sequence-specific, DNA binding proteins from random sequence oligonucleotides. Anal Biochem. 229:99–105. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Yin L, Duan JJ, Bian XW and Yu SC: Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI | |
|
Han B, Bhowmick N, Qu Y, Chung S, Giuliano AE and Cui X: FOXC1: An emerging marker and therapeutic target for cancer. Oncogene. 36:3957–3963. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Ray PS, Sim MS, Zhou XZ, Lu KP, Lee AV, Lin X, Bagaria SP, Giuliano AE and Cui X: FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappaB signaling. Oncogene. 31:4798–4802. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nieto MA: Epithelial plasticity: A common theme in embryonic and cancer cells. Science. 342:12348502013. View Article : Google Scholar : PubMed/NCBI | |
|
Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, et al: Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA. 105:14076–14081. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, et al: Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 7:e337882012. View Article : Google Scholar : PubMed/NCBI | |
|
Lindley LE and Briegel KJ: Molecular characterization of TGFbeta-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells. Biochem Biophys Res Commun. 399:659–664. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Clark KL, Halay ED, Lai E and Burley SK: Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 364:412–420. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Perumal K, Dirr HW and Fanucchi S: A single amino acid in the hinge loop region of the FOXP forkhead domain is significant for dimerisation. Protein J. 34:111–121. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Stroud JC, Wu Y, Bates DL, Han A, Nowick K, Paabo S, Tong H and Chen L: Structure of the forkhead domain of FOXP2 bound to DNA. Structure. 14:159–166. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T and Inoue S: FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer. 2:286–297. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Beelen K, Hoefnagel LD, Opdam M, Wesseling J, Sanders J, Vincent AD, van Diest PJ and Linn SC: PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. Int J Cancer. 135:1257–1263. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, Jones M, Mason DY, Prime JE, Trougouboff P, et al: The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 61:8820–8829. 2001.PubMed/NCBI | |
|
Liu Y, Chen T, Guo M, Li Y, Zhang Q, Tan G, Yu L and Tan Y: FOXA2-interacting FOXP2 prevents epithelial-mesenchymal transition of breast cancer cells by stimulating E-cadherin and PHF2 transcription. Front Oncol. 11:6050252021. View Article : Google Scholar : PubMed/NCBI | |
|
Sada f, Akhter N, Alharbi RA, Sindi AAA, Najm MZ, Alhumaydhi FA, Khan MA, Deo SVS and Husain SA: Epigenetic alteration and its association with downregulated FOXP3 gene in indian breast cancer patients. Front Genet. 12:7814002021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Han J, Li X, Huang T, Gao Y, Wang B, Zhang K, Wang S, Zhang W, Li W, et al: FOXP3 inhibits the metastasis of breast cancer by downregulating the expression of MTA1. Front Oncol. 11:6561902021. View Article : Google Scholar : PubMed/NCBI | |
|
Ma B, Miao W, Xiao J, Chen X, Xu J and Li Y: The role of FOXP3 on tumor metastasis and its interaction with traditional Chinese medicine. Molecules. 27:67062022. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, Cheng H, Chen X, Li T, Zhang J, Jin G, Cai D and Huang Z: FOXA1 is prognostic of triple negative breast cancers by transcriptionally suppressing SOD2 and IL6. Int J Biol Sci. 15:1030–1041. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cao J, Wang X, Wang D, Ma R, Li X, Feng H, Wang J, Liu S and Wang L: PGC-1β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells. Cancer Cell Int. 19:932019. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Zeng S, Zheng G, Chen D, Li P, Yang M, Luo K, Yin J, Gu Y, Zhang Z, et al: FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis. Oncogene. 40:777–790. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wei G, Yang X, Lu H, Zhang L, Wei Y, Li H, Zhu M and Zhou X: Prognostic value and immunological role of FOXM1 in human solid tumors. Aging (Albany NY). 14:9128–9148. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Broughton JP, Lovci MT, Huang JL, Yeo GW and Pasquinelli AE: Pairing beyond the seed supports microRNA targeting specificity. Mol Cell. 64:320–333. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Arora T, Kausar MA, Aboelnaga SM, Anwar S, Hussain MA, Sadaf S, Kaur S, Eisa AA, Shingatgeri VMM, Najm MZ and Aloliqi AA: miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review). Oncol Rep. 48:1352022. View Article : Google Scholar : PubMed/NCBI | |
|
Denli AM, Tops BB, Plasterk RH, Ketting RF and Hannon GJ: Processing of primary microRNAs by the microprocessor complex. Nature. 432:231–235. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Alarcón CR, Lee H, Goodarzi H, Halberg N and Tavazoie SF: N6-methyladenosine marks primary microRNAs for processing. Nature. 519:482–485. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Okada C, Yamashita E, Lee SJ, Shibata S, Katahira J, Nakagawa A, Yoneda Y and Tsukihara T: A high-resolution structure of the pre-microRNA nuclear export machinery. Science. 326:1275–1279. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Kolb FA, Jaskiewicz L, Westhof E and Filipowicz W: Single processing center models for human Dicer and bacterial RNase III. Cell. 118:57–68. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W and Luo YP: MicroRNAs in breast cancer: Oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B. 16:18–31. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Corcoran C, Friel AM, Duffy MJ, Crown J and O'Driscoll L: Intracellular and extracellular microRNAs in breast cancer. Clin Chem. 57:18–32. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X, Connick MC, Vanderhoof J, Ishak MA and Hartley RS: MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. Int J Mol Sci. 16:7112–7132. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jin T, Suk Kim H, Ki Choi S, Hye Hwang E, Woo J, Suk Ryu H, Kim K, Moon A and Kyung Moon W: microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival. Oncotarget. 8:32769–32782. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Wang Y, Ni C, Meng G and Sheng X: HLF/miR-132/TTK axis regulates cell proliferation, metastasis and radiosensitivity of glioma cells. Biomed Pharmacother. 83:898–904. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Ren J, Ren H, Fu JL and Yu D: MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1. Acta Pharmacol Sin. 39:124–131. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao T, Zou M, Shen T and Duan S: Dysfunction of miR-802 in tumors. J Clin Lab Anal. 35:e239892021. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan F and Wang W: MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. Mol Med Rep. 12:4647–4651. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Ye B, Wang P, Yao F, Zhang C and Yu G: Overview of microRNA-199a regulation in cancer. Cancer Manag Res. 11:10327–10335. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, et al: MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 15:762–774. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X and Song L: Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 5:e157972010. View Article : Google Scholar : PubMed/NCBI | |
|
Yin Z, Wang W, Qu G, Wang L, Wang X and Pan Q: MiRNA-96-5p impacts the progression of breast cancer through targeting FOXO3. Thorac Cancer. 11:956–963. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan X, Li Z, Ren S, Rezaei K, Pan Q, Goldstein AT, Macri CJ, Cao D, Brem RF and Fu SW: Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. Breast Cancer Res. 21:892019. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar U, Hu Y, Masrour N, Castellanos-Uribe M, Harrod A, May ST, Ali S, Speirs V, Coombes RC and Yagüe E: MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochem Pharmacol. 192:1146922021. View Article : Google Scholar : PubMed/NCBI | |
|
Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG and Nakshatri H: FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res. 13:4415–4421. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, et al: FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci USA. 113:E6600–E6609. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D and Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 43:27–33. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi N, Nakayama Y and Yamaguchi N: Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J Biol Chem. 292:8136–8148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR, Man EP, Khongkow P, Tsang JW, Khoo US, et al: OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene. 35:1433–1444. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL, Magalhães LM, et al: FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cell Signal. 27:2496–2505. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nestal de Moraes G, Bella L, Zona S, Burton MJ and Lam EW: Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance. Curr Drug Targets. 17:164–177. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Di Fruscia P, Zacharioudakis E, Liu C, Moniot S, Laohasinnarong S, Khongkow M, Harrison IF, Koltsida K, Reynolds CR, Schmidtkunz K, et al: The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. ChemMedChem. 10:69–82. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Saba R, Alsayed A, Zacny JP and Dudek AZ: The role of forkhead box protein M1 in breast cancer progression and resistance to therapy. Int Breast Cancer. 2016:97681832016.PubMed/NCBI | |
|
Ji X, Tian X, Feng S, Zhang L, Wang J, Guo R, Zhu Y, Yu X, Zhang Y, Du H, et al: Intermittent F-actin perturbations by magnetic fields inhibit breast cancer metastasis. Research (Wash DC). 6:00802023.PubMed/NCBI | |
|
Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL and Gartel AL: Honokiol is a FOXM1 antagonist. Cell Death Dis. 9:842018. View Article : Google Scholar : PubMed/NCBI | |
|
Rajamanickam S, Panneerdoss S, Gorthi A, Timilsina S, Onyeagucha B, Kovalskyy D, Ivanov D, Hanes MA, Vadlamudi RK, Chen Y, et al: Inhibition of FoxM1-mediated DNA repair by imipramine blue suppresses breast cancer growth and metastasis. Clin Cancer Res. 22:3524–3536. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez JS and Banerji U: Combine and conquer: Challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 14:57–66. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E and Lambertini M: Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 62:123–132. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R and Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 96:739–749. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guillen VS, Ziegler Y, Gopinath C, Kumar S, Dey P, Plotner BN, Dawson NZ, Kim SH, Katzenellenbogen JA and Katzenellenbogen BS: Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs. Breast Cancer Res Treat. 198:607–621. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Z, Huang W, He Q, Li D, Wang Z, Feng Y, Liu D, Zhang T, Wang Y, Xie M, et al: FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter. J Exp Clin Cancer Res. 40:502021. View Article : Google Scholar : PubMed/NCBI | |
|
Bader AG and Lammers P: The therapeutic potential of microRNAs. Innov Pharm Technol. 52–55. 2011. | |
|
Broderick JA and Zamore PD: MicroRNA therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME and Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 14:R792012. View Article : Google Scholar : PubMed/NCBI | |
|
Linares A, Dalenc F, Balaguer P, Boulle N and Cavailles V: Manipulating protein acetylation in breast cancer: A promising approach in combination with hormonal therapies? J Biomed Biotechnol. 2011:8569852011. View Article : Google Scholar : PubMed/NCBI | |
|
Khafaga AF, Shamma RN, Abdeen A, Barakat AM, Noreldin AE, Elzoghby AO and Sallam MA: Celecoxib repurposing in cancer therapy: Molecular mechanisms and nanomedicine-based delivery technologies. Nanomedicine (Lond). 16:1691–1712. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
National Library of Medicine (NIH), . Study to Compare Alisertib with Paclitaxel vs Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer. Clinical trial: NCT02187991. NIH; Bethesda, MD: 2022, https://www.mycancergenome.org/content/clinical_trials/NCT02187991/December 1–2022 | |
|
National Library of Medicine (NIH), . First Time in Human Study of AZD8701 With or Without Durvalumab in Participants with Advanced Solid Tumours. Clinical trial: NCT04504669. NIH; Bethesda, MD: 2022, https://www.mycancergenome.org/content/clinical_trials/NCT04504669/December 1–2022 | |
|
National Library of Medicine (NIH), . Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD). Clinical trial: NCT04443348. NIH; Bethesda, MD: 2022, https://www.mycancergenome.org/content/clinical_trials/NCT04443348/December 1–2022 | |
|
National Library of Medicine (NIH), . A Study of PDR001 in Combination with LCL161, Everolimus or Panobinostat. Clinical trial: NCT02890069. NIH; Bethesda, MD: 2022, https://www.mycancergenome.org/content/clinical_trials/NCT02890069/December 1–2022 | |
|
National Library of Medicine (NIH), . Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients with Advanced Solid Tumours. Clinical trial: NCT02260661. NIH; Bethesda, MD: 2022, https://www.mycancergenome.org/content/clinical_trials/NCT02260661/December 1–2022 |
